Taylor Wessing advises Innate Pharma S.A. on its recent in-licensing agreement with Cancer Research Technology Limited
CLIENT
Innate Pharma SA
VALUE
Not disclosed
TRANSACTION
Collaboration and licensing deal
DESCRIPTION
Advised Innate Pharma S.A. on its recent in-licensing agreement with the Cancer Research Technology Limited. The agreement grants Innate Pharma exclusive and worldwide development and commercialisation rights to a panel of discovery stage novel toll-like receptor (TLR) agents
